Altimmune announces oral presentation of pemvidutide clinical data in treatment of nafld at upcoming easl international liver congress™ 2023

Presentation selected for best of easl summary slides altimmune to host a nash kol and investor reception on june 22, 2023 gaithersburg, md., june 15, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that dr. stephen a.
ALT Ratings Summary
ALT Quant Ranking